C., Asawachaicharn, A., Gaupp, D
S/MET, Sitagliptin and Metformin, Th2, T Helper 2
SGLT2 inhibitors Empagliflozin: Empagliflozin is a novel SGLT2 inhibitor, the underlying mechanisms of which include ameliorating hyperglycemia, preventing the development of endothelial dysfunction, reducing oxidative stress, and improving metabolic profiles
While GHK-Cu is generally well-tolerated in topical research, certain contraindications or precautions should be considered, especially for systemic research or in specific populations: Systemic Research: For systemic applications, GHK-Cu is generally not recommended for subjects who are pregnant, breastfeeding, have active cancer, or suffer from Wilsons disease (a condition involving copper accumulation)